GHK-Cu
Cosmetic and Skincare
ABOUT
GHK-Cu is the copper complex of the naturally occurring tripeptide GHK. A small randomized study evaluated a topical GHK-Cu-containing skincare regimen after laser resurfacing; it did not show objective improvement in the main assessed skin outcomes.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II), forming the GHK-Cu complex. Reported activity includes antioxidant and anti-inflammatory effects and broad modulation of gene expression; in a bleomycin lung-fibrosis model the effect was mapped to Nrf2, NF-kB and TGF-beta1/Smad2/3 signalling. Copper handling is central to the mechanism, which is also why dose matters.
PHARMACOKINETICS
No absorption, distribution, metabolism or elimination data is curated. Skin-penetration data for cosmetic formulations is not reported in the reviews indexed here, so how much of a topical dose reaches living skin is not established.
REVIEW
PUBLISHED PAIR RECORDS
with KLOW
Same substance taken twice: blend already contains this compoundKLOW already contains GHK-Cu at 50 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GLOW
Same substance taken twice: blend already contains this compoundGLOW already contains GHK-Cu at 50 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
The mechanistic literature is in-vitro and rodent. The one controlled human study curated here is negative: a small randomised study of a topical copper-tripeptide regimen on CO2 laser-resurfaced skin did not show objective improvement in the main assessed outcomes. Reviews describe a long history of use in wound care and cosmetic products without citing controlled trials that support the regenerative claims, and formal human efficacy evidence for the injectable route is absent entirely.
REPORTED EFFECTS
No formal safety or irritation studies are cited in the indexed reviews. FDA placed injectable-route GHK-Cu into the Category 2 interim compounding list (substances that may present significant safety risks) while allowing certain non-injectable uses in Category 1; those interim categorisations are not final determinations. The distinction matters: topical cosmetic use and injection are not the same exposure.
RESEARCH LIMITATIONS
This is limited topical, product-specific human evidence. It does not establish effectiveness or safety for other routes, preparations, goals, or long-term use. This record is not a treatment or preparation recommendation.
CURATED SOURCES · 4